| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
EIRx Therapeutics PLC (ERX)
driver
- 30 Mar 2006 17:03
About ERIXEiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html
Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html
ERX interview with John Poolhttp://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html
Past and present collaborative partners include:
* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc
potatohead - 01 Sep 2006 09:08 - 69 of 1180
Gene therapy shrinks melanoma tumors
(MCT)
NEW YORK - Doctors wiped out melanoma by reengineering patients' own cells, marking the first time gene therapy has worked successfully against a cancer and raising hopes that the treatment can eradicate other forms of the disease.
Government scientists took healthy immune cells from patients with advanced forms of the skin cancer and taught the cells to recognize and destroy the cancer cells. Doctors then fed patients the tailor-made fighter cells intravenously, and their tumors gradually shrank.
Just two of the 17 patients in the study are still disease-free a year and a half after the treatment. But doctors said the research proved that the technique could help patients battling many forms of cancer.
"We can now convert normal lymphocytes into cells that can recognize very common cancers like breast, lung, ovary, prostate and so on. We haven't treated those patients yet, but this represents proof that this kind of approach can work," said study author Dr. Steven Rosenberg, chief of surgery at the National Cancer Institute.
The other 15 patients in the study, published in Friday's issue of the journal Science, grew low levels of the reengineered immune cells for at least two months. Since the trial began in December 2004, scientists have developed more advanced gene therapy techniques that could improve the results, Rosenberg said.
"It is totally intriguing," said Dr. Anna Pavlick, director of the NYU Cancer Institute's melanoma program.
But it's too soon to call the therapy a cure, she said.
"They didn't look at survival and they wouldn't be able to in this small group of patients. That's why it's a little bit premature to know how effective this is going to be, but nonetheless it is a treatment that needs to be studied in a larger number of patients," said Dr. Howard Kaufman, director of the tumor immunotherapy program at New York Presbyterian Hospital Columbia.
Melanoma is one of the deadliest and fastest-growing cancers in the United States. An estimated 62,190 people will develop the disease this year, and 7,910 will die of it, according to the American Cancer Society.
---
http://www.duluthsuperior.com/mld/duluthsuperior/news/nation/15414535.htm
(MCT)
NEW YORK - Doctors wiped out melanoma by reengineering patients' own cells, marking the first time gene therapy has worked successfully against a cancer and raising hopes that the treatment can eradicate other forms of the disease.
Government scientists took healthy immune cells from patients with advanced forms of the skin cancer and taught the cells to recognize and destroy the cancer cells. Doctors then fed patients the tailor-made fighter cells intravenously, and their tumors gradually shrank.
Just two of the 17 patients in the study are still disease-free a year and a half after the treatment. But doctors said the research proved that the technique could help patients battling many forms of cancer.
"We can now convert normal lymphocytes into cells that can recognize very common cancers like breast, lung, ovary, prostate and so on. We haven't treated those patients yet, but this represents proof that this kind of approach can work," said study author Dr. Steven Rosenberg, chief of surgery at the National Cancer Institute.
The other 15 patients in the study, published in Friday's issue of the journal Science, grew low levels of the reengineered immune cells for at least two months. Since the trial began in December 2004, scientists have developed more advanced gene therapy techniques that could improve the results, Rosenberg said.
"It is totally intriguing," said Dr. Anna Pavlick, director of the NYU Cancer Institute's melanoma program.
But it's too soon to call the therapy a cure, she said.
"They didn't look at survival and they wouldn't be able to in this small group of patients. That's why it's a little bit premature to know how effective this is going to be, but nonetheless it is a treatment that needs to be studied in a larger number of patients," said Dr. Howard Kaufman, director of the tumor immunotherapy program at New York Presbyterian Hospital Columbia.
Melanoma is one of the deadliest and fastest-growing cancers in the United States. An estimated 62,190 people will develop the disease this year, and 7,910 will die of it, according to the American Cancer Society.
---
http://www.duluthsuperior.com/mld/duluthsuperior/news/nation/15414535.htm
driver
- 01 Sep 2006 09:50
- 70 of 1180
sp on the move 21%.
driver
- 01 Sep 2006 18:08
- 71 of 1180
Finished a modest 4.7% up, not bad with still no news.
forest - 03 Sep 2006 13:11 - 72 of 1180
Just been on the other bb, what a load of crap being posted. Nothing in the weekend press, re erx.
driver
- 03 Sep 2006 14:40
- 73 of 1180
forest
Crap everywhere I have asked ph not to post on this thread. news will come when it's ready.
Crap everywhere I have asked ph not to post on this thread. news will come when it's ready.
mcmahons
- 04 Sep 2006 09:16
- 74 of 1180
Did anyone see the TV News item BBC 'Gene therapy shrinks melanoma tumors' Saturday 02/09/06 and was this tiddler of a company the one making the News ?
Presume it is based on early trades this morning!
Presume it is based on early trades this morning!
driver
- 04 Sep 2006 09:52
- 75 of 1180
mcmahons
Early trades this morning is based on the constant ramping on other sites ERX have made no such announcements and until they do every thing is pure speculation.
Early trades this morning is based on the constant ramping on other sites ERX have made no such announcements and until they do every thing is pure speculation.
mcmahons
- 04 Sep 2006 09:56
- 76 of 1180
cheers
potatohead - 04 Sep 2006 13:47 - 77 of 1180
ERX have got there senior scientist writting a note with regards to the guardian report last week.., I emailed it them on friday night, they responded this morning saying a note will be issued ;-).. just sit and wait now
potatohead - 04 Sep 2006 17:16 - 78 of 1180
dont know why you lot are moaning, its going up.. or have you been waiting hopeing to get in cheaper and it has dones lately is go up.. oh dear!!! thats a pity, well never you mind, back in june the ceo said the sp was significantly undervalued and the price then was the same as about now.. so its not too late to get in, you just missed getting in sub .0020p thats all..
driver
- 04 Sep 2006 17:25
- 79 of 1180
potatohead
No one is moaning I just don't want the pump and dump brigade on here some speculation is ok but not outright ramping.
No one is moaning I just don't want the pump and dump brigade on here some speculation is ok but not outright ramping.
potatohead - 05 Sep 2006 09:51 - 80 of 1180
more coverage
Scientists at Harvard University have identified key compounds that stimulate stem cell growth in the brain, which may one day lead to restored function for people affected by Parkinson's disease, strokes, multiple sclerosis, and a wide range of neurological disorders. These findings, which appear in the September 2006 issue of The FASEB Journal, provide important clues as to which compounds may be responsible for causing key brain cells, neurons, to regenerate and ultimately restore brain function.
The research study focused on two compounds--LTB4 and LXA4. Both play a role in inflammation and are regulators of proliferation of several cell types. When stem cells isolated from the brains of mouse embryos were exposed to LTB4 they proliferated and differentiated, giving rise to additional stem cells and to differentiated neurons with limited or absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis.
"This study opens doors to new therapeutic approaches for a wide range neurological disorders and injuries that were once considered incurable," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal.
The study also provided so insight into the cellular and molecular mechanisms involved when LTB4 stimulates neuronal stem cells. According to the study, cells generated as the result of LTB4 exposure had high levels of LTB4 receptors, whereas the level of LTB4 receptors was considerably lower in similar cells not generated by LTB4 stimulation. The investigators were further able to show that LTB4 up-regulated several molecules involved in cell cycling and growth, such as cyclins and epidermal growth factor receptor, and decreased those such as caspase 8 which play a role in apoptosis. LXA4 had the opposite effects.
The FASEB Journal (www.fasebj.org) is published by the Federation of American Societies for Experimental Biology (FASEB) and is consistently ranked among the top three biology journals worldwide by the Institute for Scientific Information. FASEB comprises 21 nonprofit societies with more than 80,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to enhance the ability of biomedical and life scientists to improve -- through their research -- the health, well-being and productivity of all people. FASEB serves the interests of these scientists in those areas related to public policy, facilitates coalition activities among member societies and disseminates information on biological research through scientific conferences and publications.
Scientists at Harvard University have identified key compounds that stimulate stem cell growth in the brain, which may one day lead to restored function for people affected by Parkinson's disease, strokes, multiple sclerosis, and a wide range of neurological disorders. These findings, which appear in the September 2006 issue of The FASEB Journal, provide important clues as to which compounds may be responsible for causing key brain cells, neurons, to regenerate and ultimately restore brain function.
The research study focused on two compounds--LTB4 and LXA4. Both play a role in inflammation and are regulators of proliferation of several cell types. When stem cells isolated from the brains of mouse embryos were exposed to LTB4 they proliferated and differentiated, giving rise to additional stem cells and to differentiated neurons with limited or absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis.
"This study opens doors to new therapeutic approaches for a wide range neurological disorders and injuries that were once considered incurable," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal.
The study also provided so insight into the cellular and molecular mechanisms involved when LTB4 stimulates neuronal stem cells. According to the study, cells generated as the result of LTB4 exposure had high levels of LTB4 receptors, whereas the level of LTB4 receptors was considerably lower in similar cells not generated by LTB4 stimulation. The investigators were further able to show that LTB4 up-regulated several molecules involved in cell cycling and growth, such as cyclins and epidermal growth factor receptor, and decreased those such as caspase 8 which play a role in apoptosis. LXA4 had the opposite effects.
The FASEB Journal (www.fasebj.org) is published by the Federation of American Societies for Experimental Biology (FASEB) and is consistently ranked among the top three biology journals worldwide by the Institute for Scientific Information. FASEB comprises 21 nonprofit societies with more than 80,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to enhance the ability of biomedical and life scientists to improve -- through their research -- the health, well-being and productivity of all people. FASEB serves the interests of these scientists in those areas related to public policy, facilitates coalition activities among member societies and disseminates information on biological research through scientific conferences and publications.
driver
- 05 Sep 2006 09:57
- 81 of 1180
ph
No mention of ERX in there
No mention of ERX in there
potatohead - 05 Sep 2006 10:10 - 82 of 1180
02:47ihavenoclueRE: Riskypete ... ERXBuy
You say the interview says there will be lots of good news soon. ..Mon 18:32sharedealershare price?Strong Buy
well according to some on this site E.I.R.X. are about to make an announcement in the near future as regards to future progress of the company & affiliates, this should be very positive news, in that e.i.r.x. are at the fore-front of apoposis research & development, and have already patented certain parts of their re-search that protect intellectual rights e.t.c.
they are already in colaboration with a number of companies including meryk. and have taken on board Auvation from scotland who where in the same line of business and who,s aquisition was a perfect fit according to E.I.R.X. not to mention the french company (who,s name eludes me at the moment) this company has the ability to manafacture, as well as assist in research under licence to e.i.r.x.
I would be suprised if e.i.r.x. had no imput into last weeks announcements regarding the new sucsessful approach to treating cancers, via the apoptosis route, as they are years ahead of most in this field, and possibly all, so when an announcement is made don,t be suprised by a massive surge in the share price, as the big drug companies move in an attempt to buy in, or even buy them out, as they have most to loose if an absolute cure for cancers becomes a reallity, i.e. drugs that at most control cancer will be confined to history as will their profits.
What happened last week is just the beginning of a new era in medical science, so fill you,r boots with shares of e.i.r.x. I have.
Sharedealer100.
You say the interview says there will be lots of good news soon. ..Mon 18:32sharedealershare price?Strong Buy
well according to some on this site E.I.R.X. are about to make an announcement in the near future as regards to future progress of the company & affiliates, this should be very positive news, in that e.i.r.x. are at the fore-front of apoposis research & development, and have already patented certain parts of their re-search that protect intellectual rights e.t.c.
they are already in colaboration with a number of companies including meryk. and have taken on board Auvation from scotland who where in the same line of business and who,s aquisition was a perfect fit according to E.I.R.X. not to mention the french company (who,s name eludes me at the moment) this company has the ability to manafacture, as well as assist in research under licence to e.i.r.x.
I would be suprised if e.i.r.x. had no imput into last weeks announcements regarding the new sucsessful approach to treating cancers, via the apoptosis route, as they are years ahead of most in this field, and possibly all, so when an announcement is made don,t be suprised by a massive surge in the share price, as the big drug companies move in an attempt to buy in, or even buy them out, as they have most to loose if an absolute cure for cancers becomes a reallity, i.e. drugs that at most control cancer will be confined to history as will their profits.
What happened last week is just the beginning of a new era in medical science, so fill you,r boots with shares of e.i.r.x. I have.
Sharedealer100.
potatohead - 05 Sep 2006 12:16 - 83 of 1180
the press is wrtting a lot on apoptosis - at the end of the day.. they are all using ERX methods.. so therefore, we are bound to get something. and rather big I would say, after what J Pool said in his interview.. he said very soon and that was back in June, the way the SP has been going it does look soon.. look at all the news out below, its all available on google news, just search Apoptosis
Scientists Identify Compounds That Stimulate Stem Cell Growth In ...
Haber Sağlık, Turkey - 5 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Harvard scientists report key stem cell research findings
Pharmaceutical Business Review - 9 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Malignant glioma: engineered adenovirus induces cells to die by ...
Xagena.it, Italy - 14 hours ago
... The cells showed no sign of having been killed by apoptosis. ... Many cancer therapies focus on restoring or enhancing apoptosis to combat the disease. ...
EIRX THERAPEUTICS PLC ORD 0.2P Share Price direct to your mobile ...
Life Style Extra, UK - 17 hours ago
... I would be suprised if eirx had no imput into last weeks announcements regarding the new sucsessful approach to treating cancers, via the apoptosis route, as ...
LB-18, derived from a marine sponge, induces apoptosis in ...
Therapeutics Daily (subscription) (press release), PA - 17 hours ago
... 4 - (NewsRx.com) -- Scientists have isolated a novel synthetic drug, LB-18, from a marine sponge that can induce caspase-independent apoptosis in neuroblastoma ...
Harvard Scientists Report Key Stem Cell Research Findings
International News Service, Australia - 18 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Breakthrough In The Identity Of Compounds That Encourage Stem Cell ...
MedIndia, India - 18 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Carbon Monoxide May Prevent Pre-Eclampsia
MedIndia, India - 19 hours ago
... is used, according to Bainbridge et al., who have published a paper called "Carbon monoxide inhibits hypoxia/reoxygenation-induced apoptosis and secondary ...
New hope for patients with lung and joint disease
News-Medical.net, Australia - 23 hours ago
... These drugs trigger a process of cell 'suicide' called apoptosis in which the inflammatory cells, called neutrophils, destroy themselves before being removed ...
Scientists identifiy key compounds that stimulate stem cell growth ...
News-Medical.net, Australia - 4 Sep 2006
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Scientists Identify Compounds That Stimulate Stem Cell Growth In ...
Haber Sağlık, Turkey - 5 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Harvard scientists report key stem cell research findings
Pharmaceutical Business Review - 9 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Malignant glioma: engineered adenovirus induces cells to die by ...
Xagena.it, Italy - 14 hours ago
... The cells showed no sign of having been killed by apoptosis. ... Many cancer therapies focus on restoring or enhancing apoptosis to combat the disease. ...
EIRX THERAPEUTICS PLC ORD 0.2P Share Price direct to your mobile ...
Life Style Extra, UK - 17 hours ago
... I would be suprised if eirx had no imput into last weeks announcements regarding the new sucsessful approach to treating cancers, via the apoptosis route, as ...
LB-18, derived from a marine sponge, induces apoptosis in ...
Therapeutics Daily (subscription) (press release), PA - 17 hours ago
... 4 - (NewsRx.com) -- Scientists have isolated a novel synthetic drug, LB-18, from a marine sponge that can induce caspase-independent apoptosis in neuroblastoma ...
Harvard Scientists Report Key Stem Cell Research Findings
International News Service, Australia - 18 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Breakthrough In The Identity Of Compounds That Encourage Stem Cell ...
MedIndia, India - 18 hours ago
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
Carbon Monoxide May Prevent Pre-Eclampsia
MedIndia, India - 19 hours ago
... is used, according to Bainbridge et al., who have published a paper called "Carbon monoxide inhibits hypoxia/reoxygenation-induced apoptosis and secondary ...
New hope for patients with lung and joint disease
News-Medical.net, Australia - 23 hours ago
... These drugs trigger a process of cell 'suicide' called apoptosis in which the inflammatory cells, called neutrophils, destroy themselves before being removed ...
Scientists identifiy key compounds that stimulate stem cell growth ...
News-Medical.net, Australia - 4 Sep 2006
... absent capacity to divide. When exposed to LXA4, these cells experienced decreased growth and apoptosis. "This study opens doors ...
potatohead - 05 Sep 2006 12:36 - 84 of 1180
patents ERX have a applied for
http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1
Apoptosis!!! ;-)
RESULT LIST
17 results found in the Worldwide database for:
eirx (applicant or inventor)
(Results are sorted by date of upload in database)
1 SCREENING-VERFAHREN in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE)
EC: G01N33/50D2; G01N33/543K IPC: G01N33/50; G01N33/543; G01N33/50 (+2)
Publication info: AT325889T - 2006-06-15
2 Enzymes involved in apoptosis in my patents list
Inventor: MURPHY FINBARR J (IE); SHEEHAN DYAN E (IE); (+3) Applicant: EIRX THERAPEUTICS LTD
EC: C07K14/47A33 IPC: A61K48/00; A61K38/54; C07K14/47 (+11)
Publication info: US2006121498 - 2006-06-08
3 SCREENING METHOD in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE)
EC: G01N33/50D2; G01N33/543K IPC: C12Q1/00; G01N33/50; G01N33/543 (+3)
Publication info: DE60119524D - 2006-06-14
4 Human delta-n p73 molecules and uses thereof in my patents list
Inventor: HAYES IAN; LAURENZI VINCENZO DE; (+6) Applicant: EIRX THERAPEUTICS LTD
EC: C07K14/47A1 IPC: C07K14/47; C12N15/12; A61K38/00 (+7)
Publication info: AU2002327945 - 2003-04-01
5 ELAVL-1 in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (US)
EC: C07K14/47A33 IPC: C07K14/47; C07K14/435; (IPC1-7): C12Q1/68 (+2)
Publication info: US2005042643 - 2005-02-24
6 Apoptosis-related kinase/GPCRs in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (US)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+3)
Publication info: US2005019746 - 2005-01-27
7 Apoptosis-related kinase/GPCRs in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (US)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+2)
Publication info: US2004219616 - 2004-11-04
8 KINASES AND GPCRS INVOLVED IN APOPTOSIS in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (IE); SEERY LIAM (IE); (+2)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+2)
Publication info: WO2004065959 - 2004-08-05
9 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06
10 EARLY STAGE REDOX-RELATED APOPTOSIS MODULATOR-2 (ESRAM-2) in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03054010 - 2003-07-03
11 TGNP in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33; C12Q1/68M6; (+1) IPC: C07K14/47; C12Q1/68; G01N33/50 (+8)
Publication info: WO03050302 - 2003-06-19
12 P55PIK in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33; C12N9/12B1B; (+2) IPC: C07K14/47; C12N9/12; C12Q1/68 (+12)
Publication info: WO03048361 - 2003-06-12
13 APOPTOSIS in my patents list
Inventor: HAYES IAN (IE); KROEMER GUIDO (FR); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); INST GUSTAVE ROUSSY L (FR); (+5)
EC: A61K38/46; C12Q1/48B; (+1) IPC: A61K38/46; C12Q1/48; G01N33/68 (+5)
Publication info: WO03027671 - 2003-04-03
14 MODEL SYSTEM in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTIC LTD (IE); COTTER TOM (IE); (+2)
EC: C12N15/10C; C12Q1/68P IPC: C12N15/10; C12Q1/68; C12N15/10 (+2)
Publication info: WO0231189 - 2002-04-18
15 SCREENING METHOD 2 in my patents list
Inventor: COTTER TOM (IE); DALY PETER (IE); (+3) Applicant: EIRX THERAPEUTICS LTD (IE); COTTER TOM (IE); (+4)
EC: G01N33/50D2 IPC: G01N33/50; G01N33/50; (IPC1-7): C12Q1/68 (+1)
Publication info: WO0220834 - 2002-03-14
16 Screening method 2 in my patents list
Inventor: COTTER TOM; DALY PETER; (+3) Applicant: EIRX THERAPEUTICS LTD
EC: IPC: C12Q1/68; G01N33/50; C12Q1/68 (+3)
Publication info: AU8426401 - 2002-03-22
17 SCREENING METHOD in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE) Applicant: EIRX THERAPEUTICS LTD (IE); COTTER TOM (IE); (+1)
EC: C12Q1/68A6 IPC: C12Q1/68; C12Q1/68; (IPC1-7): C12Q1/68
Publication info: WO0146468
http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1
Apoptosis!!! ;-)
RESULT LIST
17 results found in the Worldwide database for:
eirx (applicant or inventor)
(Results are sorted by date of upload in database)
1 SCREENING-VERFAHREN in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE)
EC: G01N33/50D2; G01N33/543K IPC: G01N33/50; G01N33/543; G01N33/50 (+2)
Publication info: AT325889T - 2006-06-15
2 Enzymes involved in apoptosis in my patents list
Inventor: MURPHY FINBARR J (IE); SHEEHAN DYAN E (IE); (+3) Applicant: EIRX THERAPEUTICS LTD
EC: C07K14/47A33 IPC: A61K48/00; A61K38/54; C07K14/47 (+11)
Publication info: US2006121498 - 2006-06-08
3 SCREENING METHOD in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE)
EC: G01N33/50D2; G01N33/543K IPC: C12Q1/00; G01N33/50; G01N33/543 (+3)
Publication info: DE60119524D - 2006-06-14
4 Human delta-n p73 molecules and uses thereof in my patents list
Inventor: HAYES IAN; LAURENZI VINCENZO DE; (+6) Applicant: EIRX THERAPEUTICS LTD
EC: C07K14/47A1 IPC: C07K14/47; C12N15/12; A61K38/00 (+7)
Publication info: AU2002327945 - 2003-04-01
5 ELAVL-1 in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (US)
EC: C07K14/47A33 IPC: C07K14/47; C07K14/435; (IPC1-7): C12Q1/68 (+2)
Publication info: US2005042643 - 2005-02-24
6 Apoptosis-related kinase/GPCRs in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (US)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+3)
Publication info: US2005019746 - 2005-01-27
7 Apoptosis-related kinase/GPCRs in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (US)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+2)
Publication info: US2004219616 - 2004-11-04
8 KINASES AND GPCRS INVOLVED IN APOPTOSIS in my patents list
Inventor: SEERY LIAM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTICS LTD (IE); SEERY LIAM (IE); (+2)
EC: G01N33/50D2; G01N33/50D2B; (+1) IPC: G01N33/50; G01N33/574; G01N33/50 (+2)
Publication info: WO2004065959 - 2004-08-05
9 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06
10 EARLY STAGE REDOX-RELATED APOPTOSIS MODULATOR-2 (ESRAM-2) in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03054010 - 2003-07-03
11 TGNP in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33; C12Q1/68M6; (+1) IPC: C07K14/47; C12Q1/68; G01N33/50 (+8)
Publication info: WO03050302 - 2003-06-19
12 P55PIK in my patents list
Inventor: HAYES IAN (IE); COTTER THOMAS (IE); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+3)
EC: C07K14/47A33; C12N9/12B1B; (+2) IPC: C07K14/47; C12N9/12; C12Q1/68 (+12)
Publication info: WO03048361 - 2003-06-12
13 APOPTOSIS in my patents list
Inventor: HAYES IAN (IE); KROEMER GUIDO (FR); (+2) Applicant: EIRX THERAPEUTICS LTD (IE); INST GUSTAVE ROUSSY L (FR); (+5)
EC: A61K38/46; C12Q1/48B; (+1) IPC: A61K38/46; C12Q1/48; G01N33/68 (+5)
Publication info: WO03027671 - 2003-04-03
14 MODEL SYSTEM in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE); (+1) Applicant: EIRX THERAPEUTIC LTD (IE); COTTER TOM (IE); (+2)
EC: C12N15/10C; C12Q1/68P IPC: C12N15/10; C12Q1/68; C12N15/10 (+2)
Publication info: WO0231189 - 2002-04-18
15 SCREENING METHOD 2 in my patents list
Inventor: COTTER TOM (IE); DALY PETER (IE); (+3) Applicant: EIRX THERAPEUTICS LTD (IE); COTTER TOM (IE); (+4)
EC: G01N33/50D2 IPC: G01N33/50; G01N33/50; (IPC1-7): C12Q1/68 (+1)
Publication info: WO0220834 - 2002-03-14
16 Screening method 2 in my patents list
Inventor: COTTER TOM; DALY PETER; (+3) Applicant: EIRX THERAPEUTICS LTD
EC: IPC: C12Q1/68; G01N33/50; C12Q1/68 (+3)
Publication info: AU8426401 - 2002-03-22
17 SCREENING METHOD in my patents list
Inventor: COTTER TOM (IE); HAYES IAN (IE) Applicant: EIRX THERAPEUTICS LTD (IE); COTTER TOM (IE); (+1)
EC: C12Q1/68A6 IPC: C12Q1/68; C12Q1/68; (IPC1-7): C12Q1/68
Publication info: WO0146468
potatohead - 05 Sep 2006 13:21 - 85 of 1180
RTTNews) - Gentium S.p.A. (GENT | charts | news | PowerRating) on Tuesday said it would make an oral presentation entitled, "Defibrotide Modulates Immune Functions Of Endothelial Cells - Impact For Transplantation And Cancer Therapy," to show evidence that Defibrotide can protect endothelial cells from conditioning-mediated apoptosis, which suggests that the drug may be used as a prophylactic in patients at risk for endothelial complications. The results will be presented by Gunther Eissner at the 16th European Congress of Immunology on September 7, 2006 in Paris, France.
According to the company, the evidence demonstrates that Defibrotide has anti-inflammatory activity because it prevents transendothelial migration of immune effector cells, and it can reduce the chemotherapy-induced antigenicity of endothelial cells towards allogeneic cytotoxic T lymphocytes. In addition to these endothelium stabilizing functions, recent pre-clinical evidence suggested that Defibrotide has anti-neoplastic properties, which may be due to its ability to prevent tumor angiogenesis. The results demonstrated that Defibrotide reduces blood vessel formation, when administered on a daily basis and also it reduced tumor angiogenesis in the murine dorsal skin fold chamber after inoculation of cells from the human gastric cancer TMK.
According to the company, the evidence demonstrates that Defibrotide has anti-inflammatory activity because it prevents transendothelial migration of immune effector cells, and it can reduce the chemotherapy-induced antigenicity of endothelial cells towards allogeneic cytotoxic T lymphocytes. In addition to these endothelium stabilizing functions, recent pre-clinical evidence suggested that Defibrotide has anti-neoplastic properties, which may be due to its ability to prevent tumor angiogenesis. The results demonstrated that Defibrotide reduces blood vessel formation, when administered on a daily basis and also it reduced tumor angiogenesis in the murine dorsal skin fold chamber after inoculation of cells from the human gastric cancer TMK.
smiler o
- 05 Sep 2006 13:36
- 86 of 1180
ph
Where did you get this info from ?
Where did you get this info from ?
potatohead - 05 Sep 2006 13:44 - 87 of 1180
http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1
potatohead - 05 Sep 2006 13:44 - 88 of 1180
http://v3.espacenet.com/results?IA=eirx&sf=q&CY=gb&LG=en&DB=EPODOC&st=IA&kw=eirx&Submit=SEARCH&=&=&=&=&=&PGS=10&FIRST=1
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter